Parvovirus B19 at the culprit coronary stenosis predicts outcome after stenting

European Journal of Clinical Investigation

Volumn 44, Issue 2, 2014, Pages 209-218

  Niccoli, Giampaolo ^a   Severino, Anna ^a   Pieroni, Maurizio ^a   Cosentino, Nicola ^a   Ventrone, Maria A ^a   Conte, Micaela ^a   Roberto, Marco ^a   Gallinella, Giorgio ^b   Liuzzo, Giovanna ^a   Leone, Antonio M ^a   Porto, Italo ^a   Burzotta, Francesco ^a   Trani, Carlo ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Coronary stent; In stent restenosis; Parvovirus B19; Target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; VIRUS DNA;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BALLOON; BALLOON DILATATION; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; HUMAN PARVOVIRUS B19; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; BALLOON EMBOLECTOMY; COMPLICATION; CORONARY ARTERY DISEASE; GENETICS; HEART MUSCLE REVASCULARIZATION; MEDICAL DEVICE CONTAMINATION; PARVOVIRUS INFECTION; RESTENOSIS; STENT; SUDDEN CARDIAC DEATH; VIROLOGY;

AGED; BALLOON EMBOLECTOMY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DEATH, SUDDEN, CARDIAC; DNA, VIRAL; DRUG-ELUTING STENTS; EQUIPMENT CONTAMINATION; FEMALE; HUMANS; MALE; MYOCARDIAL REVASCULARIZATION; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; STENTS; TREATMENT OUTCOME;

EID: 84892486456     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12223     Document Type: Article

References (31)

1. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95.
2. Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010;56:1783-93.
3. Lerman A. Restenosis: another "dysfunction" of the endothelium. Circulation 2005;111:8-10.
4. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586-97.
5. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006;114:1581-90.
6. Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M et al. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008;80:1243-51.
7. Kühl U, Pauschinger M, Bock T, Klingel K, Schwimmbeck CP, Seeberg B et al. Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 2003;108:945-50.
8. Yilmaz A, Mahrholdt H, Athanasiadis A, Vogelsberg H, Meinhardt G, Voehringer M et al. Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. Heart 2008;94:1456-63.
9. Shirali GS, Ni J, Chinnock RE, Johnston JK, Rosenthal GL, Bowles NE et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001;344:1498-503.
10. Vallbracht KB, Schwimmbeck PL, Kühl U, Seeberg B, Schultheiss HP. Endothelium-dependent flow-mediated vasodilation of systemic arteries is impaired in patients with myocardial virus persistence. Circulation 2004;110:2938-45.
11. Vallbracht KB, Schwimmbeck PL, Kühl U, Rauch U, Seeberg B, Schultheiss HP. Differential aspects of endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation, and myocardial leukocyte infiltrates. Circulation 2005;111:1784-91.
12. Corcioli F, Zakrzewska K, Rinieri A, Fanci R, Innocenti M, Civinini R et al. Tissue persistence of parvovirus B19 genotypes in asymptomatic persons. J Med Virol 2008;80:2005-11.
13. Koch WC. Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr Opin Infect Dis 2001;14:343-56.
14. Liu SC, Tsai CT, Wu CK, Yu MF, Wu MZ, Lin LI et al. Human parvovirus B19 infection in patients with coronary atherosclerosis. Arch Med Res 2009;40:612-7.
15. Bültmann BD, Klingel K, Sotlar K, Bock CT, Kandolf R. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch 2003;442:8-17.
16. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
17. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-45.
18. Gallinella G, Bonvicini F, Filippone C, Delbarba S, Manaresi E, Zerbini M et al. Calibrated real-time PCR for evaluation of parvovirus b19 viral load. Clin Chem 2004;50:759-62.
19. Servant-Delmas A, Lefrère JJ, Morinet F, Pillet S. Advances in human B19 erythrovirus biology. J Virol 2010;84:9658-65.
20. Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003;34:497-503.
21. Kuethe F, Lindner J, Matschke K, Wenzel JJ, Norja P, Ploetze K et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009;49:1660-6.
22. Kleinman SH, Glynn SA, Lee TH, Tobler L, Montalvo L, Todd D et al. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion 2007;47:1756-64.
23. Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, Prigent AF et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 1999;73:8762-70.
24. Mitchell LA. Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol 2002;67:267-74.
25. 2+ entry by human parvovirus B19 capsid protein VP1. J Virol 2006;80:11370-80.
26. Bültmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M et al. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 2003;34:92-5.
27. Kerr JR, McCoy M, Burke B, Mattey DL, Pravica V, Hutchinson IV. Cytokine gene polymorphisms associated with symptomatic Parvovirus B19 infection. J Clin Pathol 2003;56:725-7.
28. Maluenda G, Ben-Dor I, Gaglia MA Jr, Wakabayashi K, Mahmoudi M, Sardi G et al. Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis. Circ Cardiovasc Interv 2012;5:12-9.
29. Wyplosz B, Montalescot G, Subtil A, Dujeancourt A, Tanguy ML, Choussat R et al. Correlation between Chlamydia pneumoniae detection from coronary angioplasty balloons and atherosclerosis severity. J Am Coll Cardiol 2006;47:1229-31.
30. Schmidt-Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss HP et al. Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus b19 infection. J Infect Dis 2010;201:936-45.
31. Moulik M, Breinholt JP, Dreyer WJ, Kearney DL, Price JF, Clunie SK et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. J Am Coll Cardiol 2010;56:582-92.